Characterization of the Novel Positive Allosteric Modulator, LY2119620, at the Muscarinic M2 and M4 Receptors

被引:42
|
作者
Croy, Carrie H. [1 ]
Schober, Douglas A. [1 ]
Xiao, Hongling [1 ]
Quets, Anne [1 ]
Christopoulos, Arthur [2 ,3 ]
Felder, Christian C. [1 ]
机构
[1] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
[2] Monash Univ, Monash Inst Pharmaceut Sci, Parkville, Vic, Australia
[3] Monash Univ, Dept Pharmacol, Parkville, Vic, Australia
关键词
IN-VIVO VALIDATION; ACETYLCHOLINE-RECEPTOR; PROBE-DEPENDENCE; LIGAND; DISCOVERY; EFFICACY; IDENTIFICATION; OXOTREMORINE; XANOMELINE; INHIBITION;
D O I
10.1124/mol.114.091751
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The M-4 receptor is a compelling therapeutic target, as this receptor modulates neural circuits dysregulated in schizophrenia, and there is clinical evidence that muscarinic agonists possess both antipsychotic and procognitive efficacy. Recent efforts have shifted toward allosteric ligands to maximize receptor selectivity and manipulate endogenous cholinergic and dopaminergic signaling. In this study, we present the pharmacological characterization of LY2119620 (3-amino-5-chloro-N-cyclopropyl-4-methyl-6-[2-(4-methylpiperazin-1- yl)-2-oxoethoxy] thieno[2,3-b] pyridine-2-carboxamide), a M-2/M-4 receptor-selective positive allosteric modulator (PAM), chemically evolved from hits identified through a M-4 allosteric functional screen. Although unsuitable as a therapeutic due to M-2 receptor cross-reactivity and, thus, potential cardiovascular liability, LY2119620 surpassed previous congeners in potency and PAM activity and broadens research capabilities through its development into a radiotracer. Characterization of LY2119620 revealed evidence of probe dependence in both binding and functional assays. Guanosine 5'-[gamma-S-35]-triphosphate assays displayed differential potentiation depending on the orthosteric-allosteric pairing, with the largest cooperativity observed for oxotremorine M (Oxo-M) LY2119620. Further [H-3]Oxo-M saturation binding, including studies with guanosine-5'-[(beta, gamma)-imido] triphosphate, suggests that both the orthosteric and allosteric ligands can alter the population of receptors in the active G protein-coupled state. Additionally, this work expands the characterization of the orthosteric agonist, iperoxo, at the M-4 receptor, and demonstrates that an allosteric ligand can positively modulate the binding and functional efficacy of this high efficacy ligand. Ultimately, it was the M-2 receptor pharmacology and PAM activity with iperoxo that made LY2119620 the most suitable allosteric partner for the M-2 active-state structure recently solved (Kruse et al., 2013), a structure that provides crucial insights into the mechanisms of orthosteric activation and allosteric modulation of muscarinic receptors.
引用
收藏
页码:106 / 115
页数:10
相关论文
共 50 条
  • [41] Generation and pharmacological analysis of M2 and M4 muscarinic receptor knockout mice
    Gomeza, J
    Zhang, L
    Kostenis, E
    Felder, CC
    Bymaster, FP
    Brodkin, J
    Shannon, H
    Xia, B
    Duttaroy, A
    Deng, CX
    Wess, J
    LIFE SCIENCES, 2001, 68 (22-23) : 2457 - 2466
  • [42] Muscarinic M2 and M4 receptors in anterior cingulate cortex: relation to neuropsychiatric symptoms in dementia with Lewy bodies
    Teaktong, T
    Piggott, MA
    Mckeith, IG
    Perry, RH
    Ballard, CG
    Perry, EK
    BEHAVIOURAL BRAIN RESEARCH, 2005, 161 (02) : 299 - 305
  • [43] In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M1 Receptor, and Xanomeline, an Agonist of Muscarinic M1/M4 Receptor, in Rodents
    Mandai, Takao
    Kasahara, Maki
    Kurimoto, Emi
    Tanaka, Maiko
    Suzuki, Motohisa
    Nakatani, Atsushi
    Kimura, Haruhide
    NEUROSCIENCE, 2019, 414 : 60 - 76
  • [44] The internalization of the M2 and M4 muscarinic acetylcholine receptors involves distinct subsets of small G-proteins
    Reiner, Cindy
    Nathanson, Neil M.
    LIFE SCIENCES, 2008, 82 (13-14) : 718 - 727
  • [45] Roles of M2 and M4 muscarinic receptors in regulating acetylcholine release from myenteric neurons of mouse ileum
    Takeuchi, T
    Fujinami, K
    Goto, H
    Fujita, A
    Taketo, MM
    Manabe, T
    Matsui, M
    Hata, F
    JOURNAL OF NEUROPHYSIOLOGY, 2005, 93 (05) : 2841 - 2848
  • [46] Novel 11C-labeled positive allosteric modulators for imaging muscarinic acetylcholine receptor M4
    Deng, Xiaoyun
    Chen, Zhen
    Zhang, Xiaofei
    Shao, Tuo
    Shao, Yihan
    Liang, Steven
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [47] Discovery of structurally distinct tricyclic M4 positive allosteric modulator (PAM) chemotypes
    Temple, Kayla J.
    Long, Madeline F.
    Engers, Julie L.
    Watson, Katherine J.
    Chang, Sichen
    Luscombe, Vincent B.
    Rodriguez, Alice L.
    Niswender, Colleen M.
    Bridges, Thomas M.
    Conn, P. Jeffrey
    Engers, Darren W.
    Lindsley, Craig W.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, 30 (04)
  • [48] LY404187: A novel positive allosteric modulator of AMPA receptors
    Quirk, JC
    Nisenbaum, ES
    CNS DRUG REVIEWS, 2002, 8 (03): : 255 - 282
  • [49] Atypical muscarinic allosteric modulation:: Cooperativity between modulators and their atypical binding topology in muscarinic M2 and M2/M5 chimeric receptors
    Tränkle, C
    Dittmann, A
    Schulz, U
    Weyand, O
    Buller, S
    Jöhren, K
    Heller, E
    Birdsall, NJM
    Holzgrabe, U
    Ellis, J
    Höltje, HD
    Mohr, K
    MOLECULAR PHARMACOLOGY, 2005, 68 (06) : 1597 - 1610
  • [50] Muscarinic receptor knockout mice:: Role of muscarinic acetylcholine receptors M2, M3, and M4 in carbamylcholine-induced gallbladder contractility
    Stengel, PW
    Cohen, ML
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 301 (02): : 643 - 650